株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病治療薬市場(組換え凝固因子濃縮製剤、血漿由来凝固因子濃縮製剤、デスモプレシン、抗線維素溶解剤) - 世界産業の分析、規模、構成比、成長率、動向および予測

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

発行 Transparency Market Research 商品コード 428071
出版日 ページ情報 英文 188 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
血友病治療薬市場(組換え凝固因子濃縮製剤、血漿由来凝固因子濃縮製剤、デスモプレシン、抗線維素溶解剤) - 世界産業の分析、規模、構成比、成長率、動向および予測 Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日: 2018年12月10日 ページ情報: 英文 188 Pages
概要

当レポートでは、血友病治療薬の世界市場に注目し、今後の推移を製品タイプ、適応症、販路、および地域の別に予測するほか、産業構造、推進・抑制要因、機会、競合環境などの分析情報および主要企業のプロファイルをまとめています。

第1章 はじめに

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主要調査目的
  • 調査ハイライト

第2章 前提と調査方法

第3章 エグゼクティブサマリー - 血友病治療薬の世界市場

第4章 市場概要

  • イントロダクション
    • 製品タイプの定義
    • 産業発展史
  • 概要
  • 重要市場指標
    • 地域・国別
    • 製品・用途・販路別
    • ターゲット市場別 - 世界的状況
  • 市場動態
    • 推進要因
    • 抑制要因
    • 機会
  • 血友病治療薬世界市場の分析と予測
    • 市場収益予測(単位:100万米ドル)
  • 血友病治療薬市場 - 世界的需給状況
  • Porterのファイブフォース分析
  • バリューチェーン分析
  • 市場展望

第5章 血友病治療薬世界市場の分析と予測 - 製品タイプ別

  • イントロダクションと定義
  • 重要所見・展開
  • 重要動向
  • 市場価額予測 - 製品タイプ別
    • 組換え凝固因子濃縮製剤
    • 血漿由来凝固因子濃縮製剤
    • デスモプレシン
    • 抗線維素溶解剤
  • 製品タイプ比較マトリクス
  • 市場求心力 - 製品タイプ別

第6章 血友病治療薬世界市場の分析と予測 - 適応症別

  • イントロダクションと定義
  • 重要所見・展開
  • 重要動向
  • 市場価額予測 - 適応症別
    • A型血友病
    • B型血友病
    • その他
  • 適応症比較マトリクス
  • 市場求心力 - 適応症別

第7章 血友病治療薬世界市場の分析と予測 - 販路別

  • イントロダクションと定義
  • 重要所見・展開
  • 重要動向
  • 市場価額予測 - 販路別
    • 院内薬局
    • 医薬品小売店
    • 電子商取引
  • 販路別比較マトリクス
  • 市場求心力 - 販路別

第8章 血友病治療薬世界市場の分析と予測 - 地域別

  • 重要所見
  • 政策と規制
  • 市場価額予測 - 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中南米
    • 中東・アフリカ
  • 市場求心力 - 地域・国別

第9章 北米血友病治療薬市場の分析と予測

  • イントロダクション
    • 重要所見
  • 市場価額予測 - 製品タイプ別
    • 組換え凝固因子濃縮製剤
    • 血漿由来凝固因子濃縮製剤
    • デスモプレシン
    • 抗線維素溶解剤
  • 市場価額予測 - 適応症別
    • A型血友病
    • B型血友病
    • その他
  • 市場価額予測 - 販路別
    • 院内薬局
    • 医薬品小売店
    • 電子商取引
  • 市場価額予測 - 国別
    • 米国
    • カナダ
  • 市場求心力分析
    • 製品タイプ別
    • 適応症別
    • 販路別
    • 国別

第10章 欧州血友病治療薬市場の分析と予測

第11章 アジア太平洋地域血友病治療薬市場の分析と予測

第12章 中南米血友病治療薬市場の分析と予測

第13章 中東・アフリカ血友病治療薬市場の分析と予測

第14章 競合環境

  • 市場参入企業 - 競合マトリクス(企業階層・規模別)
  • 市場シェア分析 - 企業別
  • 企業プロファイル
図表

List of Tables

  • Table 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 02 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016-2026
  • Table 03 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016-2026
  • Table 04 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 05 Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 06 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 07 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 08 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 09 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 10 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 11 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 12 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 13 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 14 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 15 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 16 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 17 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 18 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 19 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 20 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 21 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 22 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 23 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016-2026
  • Table 24 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016-2026
  • Table 25 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026

List of Figures

  • Figure 01 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Size, by Product Type (US$ Mn), 2017
  • Figure 02 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Share Analysis by Region, 2017
  • Figure 03 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Product Type
  • Figure 04 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Disease Indication
  • Figure 05 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Distribution Channel
  • Figure 06 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 07 Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018-2026
  • Figure 08 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant coagulation factor concentrates, 2016-2026
  • Figure 09 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Plasma-derived coagulation factor concentrates, 2016-2026
  • Figure 10 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2026
  • Figure 11 Global Bispecific & Next Generation Recombinant Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 12 Global Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 13 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 14 Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 15 Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication, 2018-2026
  • Figure 16 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia A, 2016-2026
  • Figure 17 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia B, 2016-2026
  • Figure 18 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2026
  • Figure 19 Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 20 Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 21 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016-2026
  • Figure 22 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016-2026
  • Figure 23 Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016-2026
  • Figure 24 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 25 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country, 2017 and 2026
  • Figure 26 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country, 2018-2026
  • Figure 27 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 28 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018-2026
  • Figure 29 North America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 30 North America Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 31 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 32 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018-2026
  • Figure 33 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 34 North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 35 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 36 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 37 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 38 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 39 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018-2026
  • Figure 40 Europe Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 41 Europe Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 42 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 43 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018-2026
  • Figure 44 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 45 Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 46 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 47 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 48 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 49 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 50 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018-2026
  • Figure 51 Asia Pacific Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 52 Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 53 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 54 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018-2026
  • Figure 55 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 56 Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 57 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 58 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 59 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 60 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 61 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018-2026
  • Figure 62 Latin America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 63 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 64 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018-2026
  • Figure 65 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 66 Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 67 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 68 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 69 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 70 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 71 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018-2026
  • Figure 72 Middle East & Africa Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2026
  • Figure 73 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 74 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018-2026
  • Figure 75 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 76 Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018-2026
目次

Title:
Hemophilia Treatment Drugs Market (Product Type - Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication - Hemophilia A, Hemophilia B, Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Hemophilia Treatment Drugs Market - Overview

Hemophilia treatment drugs are products that are administered into the patient's body in order to replace the blood clotting factors that are missing in their blood so that the blood can clot properly. This report analyzes the current and future prospects of the hemophilia treatment drugs market based on product type, disease indication, distribution channel, and region.

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of hemophilia treatment drugs market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market value in terms of US$ Mn for product type, disease indication, distribution channel, and region for the period 2018 to 2026.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on product type, disease indication, distribution channel, and region. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the hemophilia treatment drugs market in the current and future scenario. The report also provides Porter's five force analysis that studies five factors and their impact on the hemophilia treatment drugs market.

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors would help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on region, the market has been analyzed for major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The study also covers detailed country analysis in the respective regions for the hemophilia treatment drugs market.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire Plc., Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi.

Strategic collaboration agreements and new product development was the primary strategy adopted by major market players to bolster their position in the hemophilia treatment drugs market.

The global hemophilia treatment drugs market has been segmented as follows:

  • Global Hemophilia Treatment Drugs Market, by Product Type
  • Recombinant coagulation factor concentrates
  • Factor VIII
  • Factor IX
  • Others
  • Plasma-derived coagulation factor concentrates
  • Factor VIII
  • Factor IX
  • Others
  • Others
  • Global Hemophilia Treatment Drugs Market, by Disease Indication
  • Hemophilia A
  • Hemophilia B
  • Others
  • Global Hemophilia Treatment Drugs Market, by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Hemophilia Treatment Drugs Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • South Africa
  • GCC countries
  • Rest of MEA

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hemophilia Treatment Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Market Outlook

  • 5.1. Regulatory Scenario by Region/globally
  • 5.2. Key Mergers & Acquisitions
  • 5.3. Pipeline Analysis
  • 5.4. Clinical Trial Analysis
  • 5.5. Technological Advancements

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
    • 6.3.1. Plasma derived coagulation factor concentrates
      • 6.3.1.1. Factor VIII
      • 6.3.1.2. Factor IX
      • 6.3.1.3. Others
    • 6.3.2. Recombinant coagulation factor concentrates
      • 6.3.2.1. Factor VIII
      • 6.3.2.2. Factor IX
      • 6.3.2.3. Others
    • 6.3.3. Others
  • 6.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Product Type

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Hemophilia Treatment Drugs Market Value Forecast by Disease Indication, 2016-2026
    • 7.3.1. Hemophilia A
    • 7.3.2. Hemophilia B
    • 7.3.3. Others
  • 7.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Hemophilia Treatment Drugs Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Global Hemophilia Treatment Drugs Market Attractiveness, by Country/Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
    • 10.2.1. Plasma derived coagulation factor concentrates
      • 10.2.1.1. Factor VIII
      • 10.2.1.2. Factor IX
      • 10.2.1.3. Others
    • 10.2.2. Recombinant coagulation factor concentrates
      • 10.2.2.1. Factor VIII
      • 10.2.2.2. Factor IX
      • 10.2.2.3. Others
    • 10.2.3. Others
  • 10.3. North America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
    • 10.3.1. Hemophilia A
    • 10.3.2. Hemophilia B
    • 10.3.3. Others
  • 10.4. North America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. North America Hemophilia Treatment Drugs Market Value Forecast by Country, 2016-2026
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Hemophilia Treatment Drugs Market Attractiveness Analysis
    • 10.6.1. By Product Type
    • 10.6.2. By Disease Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
    • 11.2.1. Plasma derived coagulation factor concentrates
      • 11.2.1.1. Factor VIII
      • 11.2.1.2. Factor IX
      • 11.2.1.3. Others
    • 11.2.2. Recombinant coagulation factor concentrates
      • 11.2.2.1. Factor VIII
      • 11.2.2.2. Factor IX
      • 11.2.2.3. Others
    • 11.2.3. Others
  • 11.3. Europe Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
    • 11.3.1. Hemophilia A
    • 11.3.2. Hemophilia B
    • 11.3.3. Others
  • 11.4. Europe Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Europe Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Europe Hemophilia Treatment Drugs Market Attractiveness Analysis
    • 11.6.1. By Product Type
    • 11.6.2. By Disease Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
    • 12.2.1. Plasma derived coagulation factor concentrates
      • 12.2.1.1. Factor VIII
      • 12.2.1.2. Factor IX
      • 12.2.1.3. Others
    • 12.2.2. Recombinant coagulation factor concentrates
      • 12.2.2.1. Factor VIII
      • 12.2.2.2. Factor IX
      • 12.2.2.3. Others
    • 12.2.3. Others
  • 12.3. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
    • 12.3.1. Hemophilia A
    • 12.3.2. Hemophilia B
    • 12.3.3. Others
  • 12.4. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis
    • 12.6.1. By Product Type
    • 12.6.2. By Disease Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2. Latin America Hemophilia Treatment Drugs Market Value Forecast by Product Type, 2016-2026
    • 13.2.1. Plasma derived coagulation factor concentrates
      • 13.2.1.1. Factor VIII
      • 13.2.1.2. Factor IX
      • 13.2.1.3. Others
    • 13.2.2. Recombinant coagulation factor concentrates
      • 13.2.2.1. Factor VIII
      • 13.2.2.2. Factor IX
      • 13.2.2.3. Others
  • 13.3. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
    • 13.3.1. Hemophilia A
    • 13.3.2. Hemophilia B
    • 13.3.3. Others
  • 13.4. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis
    • 13.6.1. By Product Type
    • 13.6.2. By Disease Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast

  • 14.1.Introduction
    • 14.1.1. Key Findings
  • 14.2. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
    • 14.2.1. Plasma derived coagulation factor concentrates
      • 14.2.1.1. Factor VIII
      • 14.2.1.2. Factor IX
      • 14.2.1.3. Others
    • 14.2.2. Recombinant coagulation factor concentrates
      • 14.2.2.1. Factor VIII
      • 14.2.2.2. Factor IX
      • 14.2.2.3. Others
    • 14.2.3. Others
  • 14.3. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
    • 14.3.1. Hemophilia A
    • 14.3.2. Hemophilia B
    • 14.3.3. Others
  • 14.4. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis
    • 14.6.1. By Product Type
    • 14.6.2. By Disease Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1.Market Player - Competition Matrix (by Tier and Size of companies)
  • 15.2.Market Share Analysis by Company (2017)
  • 15.3. Company Profiles
    • 15.3.1. Biotest AG.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Business Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. SWOT Analysis
      • 15.3.1.6. Strategic overview
    • 15.3.2. Bayer AG
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Business Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. SWOT Analysis
    • 15.3.3. CSL Limited
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Business Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. SWOT Analysis
      • 15.3.3.6. Strategic overview
    • 15.3.4. F. Hoffmann-La Roche Ltd.
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Business Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. SWOT Analysis
      • 15.3.4.6. Strategic overview
    • 15.3.5. Kedrion
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Business Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. SWOT Analysis
      • 15.3.5.6. Strategic overview
    • 15.3.6. Novo Nordisk A/S
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Business Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. SWOT Analysis
      • 15.3.6.6. Strategic overview
    • 15.3.7. Octapharma
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Business Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. SWOT Analysis
      • 15.3.7.6. Strategic overview
    • 15.3.8. Pfizer, Inc
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Business Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. SWOT Analysis
      • 15.3.8.6. Strategic overview
    • 15.3.9. Sanofi
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Business Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. SWOT Analysis
      • 15.3.9.6. Strategic overview
    • 15.3.10. Shire Plc.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Business Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. SWOT Analysis
      • 15.3.10.6. Strategic overview
Back to Top